Literature DB >> 28926212

Treatment outcomes of ziv-aflibercept for treatment-naïve polypoidal choroidal vasculopathy.

Errol W Chan1,2, Mohab Eldeeb2, Vishal Govindhari3, Chintan Sarvaiya4, Alay Banker4, Ahmad Mansour5,6, Jay Chhablani3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28926212     DOI： 10.1111/aos.13533

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  5 in total

1.  Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.

Authors:  Sumit Randhir Singh; Niroj Kumar Sahoo; Nallamasa Rohit Goud; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

2.  Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy.

Authors:  Kumar Anshuman; Dhanashree Ratra
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

3.  Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy - short term study.

Authors:  Sai B Mishra; Sumit R Singh; Prakhar Goyal; Renuka Chakurkar; Vishal Govindhari; Abhilash Goud; Jay Chhablani
Journal:  Saudi J Ophthalmol       Date:  2022-02-18

4.  One year outcomes of eyes with polypoidal choroidal vasculopathy with ≥20/40 visual acuity treated with anti-vascular endothelial growth factor agents.

Authors:  Sumit R Singh; Nallamasa R Goud; Abhilash Goud; Niroj K Sahoo; Raja Narayanan; Jay Chhablani
Journal:  Saudi J Ophthalmol       Date:  2022-02-18

Review 5.  Current management strategy of polypoidal choroidal vasculopathy.

Authors:  Christine P S Ho; Timothy Y Y Lai
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.